Trial Profile
A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 26 May 2016 New trial record